GlobeNewswire

Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
10/11/2026
Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer Reported topline data from the CANYON-1 Phase 1b obesity study of CRB-913 demonstrating [...]
Paragon Genomics and Intelliseq Partner to Accelerate High-Throughput Pharmacogenomic Profiling
10/11/2026
Learn more about the unique PGx capabilities enabled by the collaboration in an Innovation Spotlight presentation at AMP 2026 on November 13, 2026 FREMONT, Calif. and MURRIETA, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- [...]
AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
10/11/2026
Launched new corporate brand as AchieveRx, The Quit Company (Nasdaq: QUIT) Presented 52-week ORCA-OL data at the CHEST 2026 Annual Meeting showing that nearly one in three adults still smoking or vaping after a [...]
Krystal Biotech to Present at Upcoming Investor Conferences
10/11/2026
PITTSBURGH, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that management will take part in fireside chats and host investor meetings at the following conferences [...]
MaxCyte Reports Third Quarter 2026 Financial Results and Updates Full Year 2026 Total Revenue Guidance
10/11/2026
MaxCyte will host its third quarter 2026 earnings call today, November 10th, at 8:30 a.m. Eastern Time Third Quarter and Recent Business Highlights: Reports total revenue of $10.2 million for the third quarter of 2026, [...]
Marvel Announces Final Shank3 Data: MB-204 Highly Effective at Reversing Autism Behaviours
10/11/2026
CALGARY, Alberta, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Researchers Discover Blood-Based Warning Signal for Ovarian Cancer at its Earliest, Precancerous Stage
10/11/2026
This first-of-its-kind breakthrough opens the possibility of detection years earlier compared to current methods NEWPORT BEACH, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Hoag researchers announced a first in the world [...]
Codexis Enters into $60 Million Term Loan Facility with Trinity Capital
10/11/2026
Initial drawdown of $42.5 million to refinance existing term loan REDWOOD CITY, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading provider of enzymatic solutions for efficient and [...]
Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
10/11/2026
MELBOURNE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) today announced that it has engaged LifeSci Capital to serve as its exclusive financial advisor to assist in evaluation of [...]
MaxCyte to Acquire Akron Bio, Expanding its Offerings Across Cell Therapy Manufacturing and Expecting to Nearly Double Revenue Base
10/11/2026
Akron Bio is a leading supplier of GMP-grade reagents and ancillary materials Expands MaxCyte’s footprint across the cell therapy manufacturing workflow and establishes a combined portfolio supporting five commercially [...]
Dimora Medical Supports Empower HS 2026, Advancing Everyday Wound Care for the HS Community
10/11/2026
Silicone foam dressings featuring MegaSorb™ technology were included in attendee gift bags to support at-home management of exuding wounds New York, USA, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Dimora Medical, a pioneer in [...]
Australian ALS therapy aimed at halting disease progression and restoring function advances to Phase 2 trial
10/11/2026
Video interviews, overlay and photos here BRISBANE, Australia, Nov. 10, 2026 (GLOBE NEWSWIRE) -- An Australian-developed therapy aimed at halting the progression of amyotrophic lateral sclerosis (ALS) and restoring [...]
UsAgainstAlzheimer’s Names Danielle Carnival, Ph.D., Chief Executive Officer; Co-Founder George Vradenburg Continues as Executive Chairman
10/11/2026
Appointment builds on momentum and urgency in the fight to end Alzheimer’s WASHINGTON, Nov. 10, 2026 (GLOBE NEWSWIRE) -- UsAgainstAlzheimer’s (UsA2) today announced the appointment of Danielle Carnival, Ph.D., as Chief [...]
Nombre d’actions et de droits de vote composant le capital social
10/11/2026
NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL DISCLOSURE OF THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL Article 223-16 du Règlement général de l’Autorité des Marchés [...]
Disclosure of the Total Number of Voting Rights and Shares Forming the Share Capital
10/11/2026
NOMBRE D’ACTIONS ET DE DROITS DE VOTE COMPOSANT LE CAPITAL SOCIAL DISCLOSURE OF THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES FORMING THE SHARE CAPITAL Article 223-16 du Règlement général de l’Autorité des Marchés [...]
CVMP adopts a positive opinion for SCOVELLA®, the first therapy for hyperinsulinaemia in horses with Equine Metabolic Syndrome
10/11/2026
SCOVELLA ® was developed to reduce hyperinsulinaemia in insulin-dysregulated horses, a key underlying driver of laminitis – a common, painful inflammatory condition in horses’ hooves and significant unmet need in equine [...]
TECregen Strengthens Management Team and Board to Advance Thymus Regeneration and Lead Program TEC001
10/11/2026
Elisabeth Svanberg, MD, PhD, appointed Chief Medical Officer, adding extensive global clinical-development and regulatory expertise Thomas Hanke, PhD, joins the Board, bringing more than 30 years of immunology, drug- [...]
TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12
10/11/2026
TME Pharma provides further details on the exclusive negotiation agreement with TMS Co., Ltd. for NOX-A12 Berlin, Germany, November 10, 2026, 8.30 am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a biotech- [...]
TME Pharma fournit davantage de détails sur l'accord de négociation exclusif conclu avec TMS Co., Ltd. concernant le NOX-A12
10/11/2026
TME Pharma fournit davantage de détails sur l'accord de négociation exclusif conclu avec TMS Co., Ltd. concernant le NOX-A12 Berlin, Allemagne, le 10 novembre 2026, 8h30 CET – TME Pharma N.V. (Euronext Growth Paris: [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum